How Syngene supported a clinical-stage oncology company in manufacturing the RSM for treating a rare tumour

Learn how Syngene reduced the number of steps required to synthesize an RSM for two API candidates by 50% and successfully manufactured and supplied the GMP product to the client.

Author

Latest Blogs

Antibody drug conjugate delivering a cytotoxic payload to a cancer cell via a chemical linker

The rise of ADCs in oncology: how antibody drug conjugate therapies deliver precision

Scientists reviewing records on a tablet, process knowledge management

Tech transfer in CDMOs: avoiding the scale-up trap

Self-amplifying RNA vaccine vials and syringe representing mRNA-based therapeutics

Self-amplifying RNA: the next chapter in mRNA therapeutics

Laboratory glassware with green leaves illustrating green chemistry in pharmaceuticals.

Green chemistry principles for a sustainable future in pharma

Integrated drug discovery scientist analysing digital lab data

Integrated Drug Discovery: why expertise matters

Bispecific antibodies: engineering complexity into simplicity

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details